Back to Search
Start Over
Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila
- Source :
- Antimicrobial Agents and Chemotherapy, Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (3), ⟨10.1128/AAC.02188-16⟩, Antimicrobial Agents and Chemotherapy, 2017, 61 (3), ⟨10.1128/AAC.02188-16⟩
- Publication Year :
- 2017
- Publisher :
- HAL CCSD, 2017.
-
Abstract
- Monitoring the emergence of antibiotic resistance is a recent issue in the treatment of Legionnaires' disease. Macrolides are recommended as first-line therapy, but resistance mechanisms have not been studied in Legionella species. Our aim was to determine the molecular basis of macrolide resistance in L. pneumophila . Twelve independent lineages from a common susceptible L. pneumophila ancestral strain were propagated under conditions of erythromycin or azithromycin pressure to produce high-level macrolide resistance. Whole-genome sequencing was performed on 12 selected clones, and we investigated mutations common to all lineages. We reconstructed the dynamics of mutation for each lineage and demonstrated their involvement in decreased susceptibility to macrolides. The resistant mutants were produced in a limited number of passages to obtain a 4,096-fold increase in erythromycin MICs. Mutations affected highly conserved 5-amino-acid regions of L4 and L22 ribosomal proteins and of domain V of 23S rRNA (G2057, A2058, A2059, and C2611 nucleotides). The early mechanisms mainly affected L4 and L22 proteins and induced a 32-fold increase in the MICs of the selector drug. Additional mutations related to 23S rRNA mostly occurred later and were responsible for a major increase of macrolide MICs, depending on the mutated nucleotide, the substitution, and the number of mutated genes among the three rrl copies. The major mechanisms of the decreased susceptibility to macrolides in L. pneumophila and their dynamics were determined. The results showed that macrolide resistance could be easily selected in L. pneumophila and warrant further investigations in both clinical and environmental settings.
- Subjects :
- 0301 basic medicine
Ribosomal Proteins
Lineage (genetic)
030106 microbiology
Drug Resistance
Erythromycin
Microbial Sensitivity Tests
ribosomal mutations
Azithromycin
medicine.disease_cause
Legionella pneumophila
Microbiology
resistance
03 medical and health sciences
Antibiotic resistance
Bacterial Proteins
Ribosomal protein
23S ribosomal RNA
Mechanisms of Resistance
Drug Resistance, Bacterial
medicine
Protein Isoforms
Pharmacology (medical)
Pharmacology
Ribosomal
Mutation
biology
Bacterial
High-Throughput Nucleotide Sequencing
23S rRNA
macrolide
Ribosomal RNA
biology.organism_classification
23S
[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
3. Good health
Anti-Bacterial Agents
Clone Cells
RNA, Ribosomal, 23S
Infectious Diseases
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
RNA
[SDV.IMM]Life Sciences [q-bio]/Immunology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 00664804 and 10986596
- Database :
- OpenAIRE
- Journal :
- Antimicrobial Agents and Chemotherapy, Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (3), ⟨10.1128/AAC.02188-16⟩, Antimicrobial Agents and Chemotherapy, 2017, 61 (3), ⟨10.1128/AAC.02188-16⟩
- Accession number :
- edsair.doi.dedup.....f019044ac0e5153066d2ed873a772090
- Full Text :
- https://doi.org/10.1128/AAC.02188-16⟩